136 related articles for article (PubMed ID: 35176452)
1. Jumonji-C domain-containing protein 5 suppresses proliferation and aerobic glycolysis in pancreatic cancer cells in a c-Myc-dependent manner.
Wang H; Wang J; Liu J; Wang Y; Xia G; Huang X
Cell Signal; 2022 May; 93():110282. PubMed ID: 35176452
[TBL] [Abstract][Full Text] [Related]
2. JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1α-mediated glucose metabolism.
Wang HJ; Hsieh YJ; Cheng WC; Lin CP; Lin YS; Yang SF; Chen CC; Izumiya Y; Yu JS; Kung HJ; Wang WC
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):279-84. PubMed ID: 24344305
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription of CDKN1A 686.
Wu BH; Chen H; Cai CM; Fang JZ; Wu CC; Huang LY; Wang L; Han ZG
Oncotarget; 2016 Feb; 7(6):6847-63. PubMed ID: 26760772
[TBL] [Abstract][Full Text] [Related]
4. JMJD5 inhibits lung cancer progression by regulating glucose metabolism through the p53/TIGAR pathway.
Liu G; Qi H; Shen J
Med Oncol; 2023 Apr; 40(5):145. PubMed ID: 37043051
[TBL] [Abstract][Full Text] [Related]
5. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer.
Qin Y; Hu Q; Ji S; Xu J; Dai W; Liu W; Xu W; Sun Q; Zhang Z; Ni Q; Yu X; Zhang B; Xu X
Cell Prolif; 2019 May; 52(3):e12603. PubMed ID: 30932257
[TBL] [Abstract][Full Text] [Related]
6. JMJD5 interacts with p53 and negatively regulates p53 function in control of cell cycle and proliferation.
Huang X; Zhang S; Qi H; Wang Z; Chen HW; Shao J; Shen J
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2286-95. PubMed ID: 26025680
[TBL] [Abstract][Full Text] [Related]
7. A novel protein encoded by ZCRB1-induced circHEATR5B suppresses aerobic glycolysis of GBM through phosphorylation of JMJD5.
Song J; Zheng J; Liu X; Dong W; Yang C; Wang D; Ruan X; Zhao Y; Liu L; Wang P; Zhang M; Liu Y
J Exp Clin Cancer Res; 2022 May; 41(1):171. PubMed ID: 35538499
[TBL] [Abstract][Full Text] [Related]
8. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis.
Qin Y; Hu Q; Xu J; Ji S; Dai W; Liu W; Xu W; Sun Q; Zhang Z; Ni Q; Zhang B; Yu X; Xu X
Cell Commun Signal; 2019 Mar; 17(1):30. PubMed ID: 30922330
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Yang CY; Tsao CH; Hsieh CC; Lin CK; Lin CS; Li YH; Chang WC; Cheng JC; Lin GJ; Sytwu HK; Wang YL; Chen YW
PLoS One; 2020; 15(7):e0236101. PubMed ID: 32678829
[TBL] [Abstract][Full Text] [Related]
10. The c-Myc-LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer.
He TL; Zhang YJ; Jiang H; Li XH; Zhu H; Zheng KL
Med Oncol; 2015 Jul; 32(7):187. PubMed ID: 26021472
[TBL] [Abstract][Full Text] [Related]
11. MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism.
Shukla SK; Gunda V; Abrego J; Haridas D; Mishra A; Souchek J; Chaika NV; Yu F; Sasson AR; Lazenby AJ; Batra SK; Singh PK
Oncotarget; 2015 Aug; 6(22):19118-31. PubMed ID: 26046375
[TBL] [Abstract][Full Text] [Related]
12. JMJD5, a Jumonji C (JmjC) domain-containing protein, negatively regulates osteoclastogenesis by facilitating NFATc1 protein degradation.
Youn MY; Yokoyama A; Fujiyama-Nakamura S; Ohtake F; Minehata K; Yasuda H; Suzuki T; Kato S; Imai Y
J Biol Chem; 2012 Apr; 287(16):12994-3004. PubMed ID: 22375008
[TBL] [Abstract][Full Text] [Related]
13. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of LncRNA LINC00261 promotes c-myc-mediated aerobic glycolysis by regulating miR-222-3p/HIPK2/ERK axis and sequestering IGF2BP1.
Zhai S; Xu Z; Xie J; Zhang J; Wang X; Peng C; Li H; Chen H; Shen B; Deng X
Oncogene; 2021 Jan; 40(2):277-291. PubMed ID: 33122827
[TBL] [Abstract][Full Text] [Related]
15. JMJD5 is a potential oncogene for colon carcinogenesis.
Zhang R; Huang Q; Li Y; Song Y; Li Y
Int J Clin Exp Pathol; 2015; 8(6):6482-9. PubMed ID: 26261525
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-κB pathway.
Yao Y; Zhou WY; He RX
Biomed Pharmacother; 2019 Jan; 109():1994-2004. PubMed ID: 30551455
[TBL] [Abstract][Full Text] [Related]
17. Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis.
Guo J; Hao J; Jiang H; Jin J; Wu H; Jin Z; Li Z
Cancer Lett; 2017 Feb; 386():161-167. PubMed ID: 27756569
[TBL] [Abstract][Full Text] [Related]
18. CLDN6 Suppresses c-MYC-Mediated Aerobic Glycolysis to Inhibit Proliferation by TAZ in Breast Cancer.
Qu H; Qi D; Wang X; Dong Y; Jin Q; Wei J; Quan C
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008557
[TBL] [Abstract][Full Text] [Related]
19. FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer.
Ji S; Qin Y; Liang C; Huang R; Shi S; Liu J; Jin K; Liang D; Xu W; Zhang B; Liu L; Liu C; Xu J; Ni Q; Chiao PJ; Li M; Yu X
Clin Cancer Res; 2016 Aug; 22(15):3950-60. PubMed ID: 26983463
[TBL] [Abstract][Full Text] [Related]
20. HMGA1 promoting gastric cancer oncogenic and glycolytic phenotypes by regulating c-myc expression.
Cao XP; Cao Y; Zhao H; Yin J; Hou P
Biochem Biophys Res Commun; 2019 Aug; 516(2):457-465. PubMed ID: 31229266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
